Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis

被引：9

作者：

Cerrato, Chiara ^{[1
]}

Di Raimondo, Francesco ^{[2
]}

De Paoli, Lorenzo ^{[3
,4
]}

Spada, Stefano ^{[1
]}

Patriarca, Francesca ^{[5
]}

Crippa, Claudia ^{[6
]}

Mina, Roberto ^{[1
]}

Guglielmelli, Tommasina ^{[7
]}

Ben-Yehuda, Dina ^{[8
]}

Oddolo, Daniela ^{[1
]}

Nozzoli, Chiara ^{[9
]}

Angelucci, Emanuele ^{[10
]}

Cascavilla, Nicola ^{[11
]}

Rizzi, Rita ^{[12
]}

Rocco, Stefano ^{[13
]}

Baldini, Luca ^{[14
]}

Ponticelli, Elena ^{[1
]}

Marcatti, Magda ^{[15
]}

Cangialosi, Clotilde ^{[16
]}

Caravita, Tommaso ^{[17
]}

Benevolo, Giulia ^{[18
]}

Ria, Roberto ^{[19
]}

Nagler, Arnon ^{[20
]}

Musto, Pellegrino ^{[21
]}

Tacchetti, Paola ^{[22
]}

Corradini, Paolo ^{[23
]}

Offidani, Massimo ^{[24
]}

Palumbo, Antonio ^{[1
,26
]}

Petrucci, Maria Teresa ^{[25
]}

Boccadoro, Mario ^{[1
]}

Gay, Francesca ^{[1
]}

机构：

[1] Univ Torino, Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Myeloma Unit, Via Genova 3, I-10126 Turin, Italy

[2] Univ Catania, Azienda Policlin OVE, UOC Ematol, Catania, Italy

[3] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[4] Maggiore Hosp, Novara, Italy

[5] Univ Udine, Dipartimento Med, Udine, Italy

[6] Spedali Civili Brescia, Div Ematol, Brescia, Italy

[7] Dept Clin & Biol Sci, Orbassano, TO, Italy

[8] Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel

[9] SODc Terapie Cellulari & Med Trasfus AOUC Careggi, Florence, Italy

[10] IRCCS Azienda Osped Univ San Martino, IST Ist Nazl Ric Canc, Genoa, Italy

[11] Hematol Casa Sollievo Sofferenza Hosp IRCCS, San Giovanni Rotondo, FG, Italy

[12] Univ Bari, Sect Hematol Transplantat, Dept Emergency & Organ Transplantat, Sch Med, Bari, Italy

[13] UOSC Ematol Trapianto AORN Cardarelli Napoli, Naples, Italy

[14] Univ Milan, Dept Oncol & Hematooncol, Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Milan, Italy

[15] IRCCS Osped San Raffaele, UO Ematol & Trapianto Midollo, Milan, Italy

[16] Osped Riuniti Villa Sofia Cervello, Unita Operat Ematol I & UTMO, Palermo, Italy

[17] UOC Ematol Osped S Eugenio ASL RM2, Rome, Italy

[18] Citta Salute & Sci Hosp, SC Hematol, Turin, Italy

[19] Univ Bari Aldo Moro, Dept Biomed Sci, Sch Med, Internal Med G Baccelli, Bari, Italy

[20] Chaim Sheba Med Ctr, Div Hematol, Ramat Gan, Israel

[21] IRCCS Referral Canc Ctr Basilicata, Sci Direct, Rionero In Vulture, PZ, Italy

[22] Bologna Univ, Sch Med, Dept Expt Diagnost & Specialty Med, Seragnoli Inst Hematol, Bologna, Italy

[23] Univ Milan, Dept Oncol & Hematol, Milan, Italy

[24] AOU Osped Riuniti Ancona, Clin Ematol, Ancona, Italy

[25] Sapienza Univ Rome, Hematol, Rome, Italy

[26] Takeda, Zurich, Switzerland

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2018年 / 144卷 / 07期

关键词：

Multiple myeloma (MM); Maintenance therapy; Newly diagnosed; Complete response (CR); Prognosis; STEM-CELL TRANSPLANTATION; BORTEZOMIB-MELPHALAN-PREDNISONE; MINIMAL RESIDUAL DISEASE; MULTIPLE-MYELOMA; INITIAL TREATMENT; THALIDOMIDE; LENALIDOMIDE; DEXAMETHASONE; METAANALYSIS; CRITERIA;

D O I：

10.1007/s00432-018-2641-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Maintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of maintenance according to response after induction/consolidation has not been investigated so far. To evaluate the impact of maintenance according to response, we pooled together and retrospectively analyzed data from 955 NDMM patients enrolled in two trials (GIMEMA-MM-03-05 and RV-MM-PI-209). Primary endpoints were progression-free survival (PFS)1, PFS2 and overall survival (OS) of CR patients randomized to maintenance and no maintenance. Secondary endpoints were PFS1, PFS2 and OS in very good partial response/partial response (VGPR/PR) patients. Overall, 213 patients obtained CR after induction/consolidation, 118 received maintenance and 95 no maintenance. In patients achieving CR, maintenance significantly improved PFS1 (HR 0.50, P < 0.001), PFS2 (HR 0.58, P 0.02) and OS (HR 0.51, P 0.02) compared with no maintenance; the advantage was maintained across all the analyzed subgroups according to age, International Staging System (ISS) stage, cytogenetic profile and treatment. Similar features were seen in VGPR/PR patients. Maintenance prolonged survival in CR and in VGPR/PR patients. The benefit in CR patients suggests the importance of continuing treatment in patients with chemo-sensitive disease. The two source studies are registered at ClinicalTrials.gov: identification numbers NCT01063179 and NCT00551928.

引用

页码：1357 / 1366

页数：10

共 50 条

[1] Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Chiara Cerrato
Francesco Di Raimondo
Lorenzo De Paoli
Stefano Spada
Francesca Patriarca
Claudia Crippa
Roberto Mina
Tommasina Guglielmelli
Dina Ben-Yehuda
Daniela Oddolo
Chiara Nozzoli
Emanuele Angelucci
Nicola Cascavilla
Rita Rizzi
Stefano Rocco
Luca Baldini
Elena Ponticelli
Magda Marcatti
Clotilde Cangialosi
Tommaso Caravita
Giulia Benevolo
Roberto Ria
Arnon Nagler
Pellegrino Musto
Paola Tacchetti
Paolo Corradini
Massimo Offidani
Antonio Palumbo
Maria Teresa Petrucci
Mario Boccadoro
Francesca Gay
Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1357 - 1366
[2] Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
Cerrato, Chiara
Gay, Francesca
Petrucci, Maria Teresa
Musto, Pellegrino
Gaidano, Gianluca
Offidani, Massimo
Guglielmelli, Tommasina
Salvini, Marco
Patriarca, Francesca
Ponticelli, Elena
Semenzato, Gianpietro
Di Raimondo, Francesco
Mina, Roberto
Cascavilla, Nicola
Ben Yehuda, Dina
Oddolo, Daniela
Corradini, Paolo
Catalano, Lucio
Di Bartolomeo, Paolo
Hajek, Roman
Spencer, Andrew
Boccadoro, Mario
Palumbo, Antonio
BLOOD, 2015, 126 (23)
[3] ROLE OF HEAVY/LIGHT CHAIN RATIO IN MYELOMA PATIENTS ACHIEVING COMPLETE RESPONSE AFTER FIRST LINE THERAPY
D'auria, F.
La Rocca, F.
Simeon, V.
Statuto, T.
Pietrantuono, G.
D'Arena, G.
Villani, O.
Mansueto, G.
Patriarca, A.
Bitetti, C.
Seneca, E.
Traficante, A.
Musto, P.
HAEMATOLOGICA, 2017, 102 : 516 - 517
[4] ROLE OF HEVYLITE® EVALUATION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE RESPONSE AFTER TREATMENT
La Rocca, F.
D'Auria, F.
Statuto, T.
Simeon, V.
Guariglia, R.
Pietrantuono, G.
Villani, O.
Mansueto, G.
D'Arena, G.
Criscuolo, C.
Izzo, T.
Laurenzana, I.
Trino, S.
De Luca, L.
Caivano, A.
Musto, P.
HAEMATOLOGICA, 2015, 100 : 99 - 99
[5] The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
Terragna, Carolina
Remondini, Daniel
Martello, Marina
Zamagni, Elena
Pantani, Lucia
Patriarca, Francesca
Pezzi, Annalisa
Levi, Giuseppe
Offidani, Massimo
Proserpio, Ilaria
De Sabbata, Giovanni
Tacchetti, Paola
Cangialosi, Clotilde
Ciambelli, Fabrizio
Vigano, Clara Virginia
Dico, Flores Angela
Santacroce, Barbara
Borsi, Enrica
Brioli, Annamaria
Marzocchi, Giulia
Castellani, Gastone
Martinelli, Giovanni
Palumbo, Antonio
Cavo, Michele
ONCOTARGET, 2016, 7 (09) : 9666 - 9679
[6] Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
Moustafa, M. Alhaj
Rajkumar, S. V.
Dispenzieri, A.
Gertz, M. A.
Lacy, M. Q.
Buadi, F. K.
Hwa, Y. L.
Dingli, D.
Kapoor, P.
Hayman, S. R.
Lust, J. A.
Kyle, R. A.
Kumar, S. K.
LEUKEMIA, 2015, 29 (10) : 2033 - 2038
[7] Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
M Alhaj Moustafa
S V Rajkumar
A Dispenzieri
M A Gertz
M Q Lacy
F K Buadi
Y L Hwa
D Dingli
P Kapoor
S R Hayman
J A Lust
R A Kyle
S K Kumar
Leukemia, 2015, 29 : 2033 - 2038
[8] UPFRONT OR RESCUE TRANSPLANT IN YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POOLED ANALYSIS OF 529 PATIENTS
Gay, F.
Magarotto, V.
Spencer, A.
Di Raimondo, F.
Pour, L.
Scudla, V.
Genuardi, M.
Carella, A. M.
Liberati, A. M.
Spada, S.
Evangelista, A.
Omede, P.
Nagler, A.
Zambello, R.
Troia, R.
Rossi, G.
Offidani, M.
Oliva, S.
Malfitano, A.
Ben Yehuda, D.
Patriarca, F.
Salvini, M.
Corradini, P.
Foa, R.
Cascavilla, N.
Pulini, S.
Petrucci, M. T.
Hajek, R.
Boccadoro, M.
Palumbo, A.
HAEMATOLOGICA, 2016, 101 : 3 - 3
[9] Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response
Fukumoto, Kota
Fujisawa, Manabu
Suehara, Yasuto
Narita, Ken-Taro
Usui, Yoshiaki
Takeuchi, Masami
Matsue, Kosei
LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1786 - 1792
[10] Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
SV Rajkumar
R Fonseca
TE Witzig
MA Gertz
PR Greipp
Leukemia, 1999, 13 : 469 - 472

← 1 2 3 4 5 →